FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice

Journal of Clinical Investigation

Volumn 122, Issue 9, 2012, Pages 3211-3220

  Lee, Sun Young ^a,b   Meier, Roland ^a,c   Furuta, Saori ^a   Lenburg, Marc E ^a,d   Kenny, Paraic A ^a,e   Xu, Ren ^a,f   Bissell, Mina J ^a  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b Pusan National University   (South Korea)

^c GENENTECH INC   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FAM83A PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PEPTIDES AND PROTEINS; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P85; RAF PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RESISTANCE; CELL INVASION; CELL PROLIFERATION; CELL TRANSFORMATION; CLONOGENESIS; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; RNA INTERFERENCE; TUMOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-RAF; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TYRPHOSTINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865982926     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI60498     Document Type: Article

References (60)

1. Rimawi MF, et al. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer. 2010;116(5):1234-1242.
2. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358(11):1160-1174.
3. Lynch TJ, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139. (Pubitemid 38637993)
4. Paez JG, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-1500. (Pubitemid 38720929)
5. Mueller KL, Hunter LA, Ethier SP, Boerner JL. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res. 2008;68(9):3314-3322.
6. Bhargava R, et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol. 2005;123(8):889-895.
7. Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R, Colomer R. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleocytoplasmic trafficking of HER-ligands. Int J Mol Med. 2007;20(1):3-10.
8. Weaver VM, et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol. 1997;137(1):231-245. (Pubitemid 27167310)
9. Briand P, Nielsen KV, Madsen MW, Petersen OW. Trisomy 7p and malignant transformation of human breast epithelial cells following epidermal growth factor withdrawal. Cancer Res. 1996;56(9):2039-2044. (Pubitemid 26119905)
10. Briand P, Petersen OW, Van Deurs B. A new diploid nontumorigenic human breast epithelial cell line isolated and propagated in chemically defined medium. In Vitro Cell Dev Biol. 1987;23(3):181-188.
11. Petersen OW, Ronnov-Jessen L, Howlett AR, Bissell MJ. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci U S A. 1992;89(19):9064-9068.
12. Wang F, et al. Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc Natl Acad Sci U S A. 1998;95(25):14821-14826. (Pubitemid 29003714)
13. Itoh M, Nelson CM, Myers CA, Bissell MJ. Rap1 integrates tissue polarity, lumen formation, and tumorigenic potential in human breast epithelial cells. Cancer Res. 2007;67(10):4759-4766. (Pubitemid 46910183)
14. Liu H, Radisky DC, Wang F, Bissell MJ. Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells. J Cell Biol. 2004;164(4):603-612. (Pubitemid 38233321)
15. Bissell MJ, Kenny PA, Radisky DC. Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol. 2005;70:343-356. (Pubitemid 44124889)
16. Li Y, et al. BJ-TSA-9, a novel human tumor-specific gene, has potential as a biomarker of lung cancer. Neoplasia. 2005;7(12):1073-1080. (Pubitemid 44430986)
17. Ferraro E, Peluso D, Via A, Ausiello G, Helmer-Citterich M. SH3-Hunter: discovery of SH3 domain interaction sites in proteins. Nucleic Acids Res. 2007;35(web server issue):W451-W454.
18. Mayer BJ. SH3 domains: complexity in moderation. J Cell Sci. 2001;114(pt 7):1253-1263. (Pubitemid 32409462)
19. Hawthorn L, Luce J, Stein L, Rothschild J. Integration of transcript expression, copy number and LOH analysis of infiltrating ductal carcinoma of the breast. BMC cancer. 2010;10:460.
20. Hegde PS, et al. Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol Cancer Ther. 2007;6(5):1629-1640. (Pubitemid 46954030)
21. Konecny GE, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66(3):1630-1639. (Pubitemid 43259947)
22. Banasiak D, Barnetson AR, Odell RA, Mameghan H, Russell PJ. Comparison between the clonogenic, MTT, and SRB assays for determining radiosensitivity in a panel of human bladder cancer cell lines and a ureteral cell line. Radiat Oncol Investig. 1999;7(2):77-85. (Pubitemid 29214708)
23. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazoliumbased semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987;47(4):936-942. (Pubitemid 17027905)
24. Kakunaga T. A quantitative system for assay of malignant transformation by chemical carcinogens using a clone derived from BALB-3T3. Int J Cancer. 1973;12(2):463-473.
25. Shih C, Padhy LC, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature. 1981;290(5803):261-264. (Pubitemid 11149660)
26. Rizki A, Mott JD, Bissell MJ. Polo-like kinase 1 is involved in invasion through extracellular matrix. Cancer Res. 2007;67(23):11106-11110. (Pubitemid 350248532)
27. Petrelli F, Cabiddu M, Cazzaniga M, Cremonesi M, Barni S. Targeted therapies for the treatment of breast cancer in the post-trastuzumab era. Oncologist. 2008;13(4):373-381. (Pubitemid 351679916)
28. Muhsin M, Graham J, Kirkpatrick P. Gefitinib. Nat Rev Drug Discov. 2003;2(7):515-516.
29. Rizki A, et al. A human breast cell model of preinvasive to invasive transition. Cancer Res. 2008;68(5):1378-1387. (Pubitemid 351346845)
30. Kenny PA, et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol. 2007;1(1):84-96. (Pubitemid 46776616)
31. Giricz O, Calvo V, Pero SC, Krag DN, Sparano JA, Kenny PA. GRB7 is required for triple-negative breast cancer cell invasion and survival. Breast Cancer Res Treat. 2012;133(2):607-615.
32. Pawitan Y, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005;7(6):R953-R964.
33. Haverty PM, et al. High-resolution genomic and expression analyses of copy number alterations in breast tumors. Genes Chromosomes Cancer. 2008;47(6):530-542. (Pubitemid 351657188)
34. Micke P, et al. Gene copy number aberrations are associated with survival in histologic subgroups of non-small cell lung cancer. J Thorac Oncol. 2011;6(11):1833-1840.
35. Coldren CD, et al. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res. 2006;4(8):521-528. (Pubitemid 44341362)
36. Bjorge J, Chan T, Antczak M, Kung H, Fujita D. Activated type I phosphatidylinositol kinase is associated with the epidermal growth factor (EGF) receptor following EGF stimulation. Proc Natl Acad Sci U S A. 1990;87(10):3816-3820.
37. Wang F, et al. Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J Natl Cancer Inst. 2002;94(19):1494-1503. (Pubitemid 35243746)
38. Kolch W, Heidecker G, Lloyd P, Rapp UR. Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature. 1991;349(6308):426-428. (Pubitemid 21926105)
39. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875-885. (Pubitemid 39486539)
40. Castellano E, Downward J. RAS interaction with PI3K: more than just another effector pathway. Genes Cancer. 2011;2(3):261-274.
41. Moodie SA, Wolfman A. The 3Rs of life: Ras, Raf and growth regulation. Trends Genet. 1994;10(2):44-48. (Pubitemid 24052926)
42. Thamilselvan V, Craig DH, Basson MD. FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway. FASEB J. 2007;21(8):1730-1741. (Pubitemid 46855619)
43. Xie D, et al. DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc Natl Acad Sci U S A. 2009;106(47):19878-19883.
44. Zheng CF, Guan KL. Properties of MEKs, the kinases that phosphorylate and activate the extracellular signal-regulated kinases. J Biol Chem. 1993;268(32):23933-23939.
45. Sholl LM, et al. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol. 2010;133(6):922-934.
46. Tsao MS, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med. 2005;353(2):133-144.
47. Generali D, et al. EGFR mutations in exons 18-21 in sporadic breast cancer. Ann Oncol. 2007;18(1):203-205. (Pubitemid 46152528)
48. Baselga J, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol. 2005;23(23):5323-5333. (Pubitemid 46206986)
49. Green MD, et al. Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Ann Oncol. 2009;20(11):1813-1817.
50. Irwin ME, Mueller KL, Bohin N, Ge Y, Boerner JL. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol. 2011;226(9):2316-2328.
51. Cipriano R, et al. FAM83B mediates EGFR- and RAS-driven oncogenic transformation. J Clin Invest. 2012;122(9):3197-3210.
52. Arcaro A, et al. Critical role for lipid raft-associated Src kinases in activation of PI3K-Akt signalling. Cell Signal. 2007;19(5):1081-1092. (Pubitemid 46437438)
53. Hekman M, et al. Associations of B- and C-Raf with cholesterol, phosphatidylserine, and lipid second messengers: preferential binding of Raf to artificial lipid rafts. J Biol Chem. 2002;277(27):24090-24102. (Pubitemid 34951922)
54. Koh EY, Chen T, Daley GQ. Novel retroviral vectors to facilitate expression screens in mammalian cells. Nucleic Acids Res. 2002;30(24):e142.
55. Lochter A, Srebrow A, Sympson CJ, Terracio N, Werb Z, Bissell MJ. Misregulation of stromelysin-1 expression in mouse mammary tumor cells accompanies acquisition of stromelysin-1-dependent invasive properties. J Biol Chem. 1997;272(8):5007-5015. (Pubitemid 27090053)
56. Ella KM, Meier GP, Bradshaw CD, Huffman KM, Spivey EC, Meier KE. A fluorescent assay for agonist-activated phospholipase D in mammalian cell extracts. Anal Biochem. 1994;218(1):136-142.
57. Gril B, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst. 2008;100(15):1092-1103.
58. Miller LD, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005;102(38):13550-13555. (Pubitemid 41420886)
59. Liu G, et al. NetAffx: Affymetrix probesets and annotations. Nucleic Acids Res. 2003;31(1):82-86.
60. Gentleman RC, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.